February 16, 2017 / 11:28 IST
GSK Consumer’s (GSK) Q3FY17 revenue (down 11.7% YoY) came in line, while EBITDA (down 9.5%) and PAT (down 8.3%) slightly surpassed our estimates. Domestic health food drinks’ (HFD) and overall company volumes plummeted 17% YoY.
Outlook
In our view, this also reflects increased competition from Patanjali Powervita, Sri Sri Ojasvita and substitutes such as Hershey’s syrup. Gross margin fell 93bps YoY as commodity prices (especially milk, sugar) have started inching up. A&P spends remained soft yet again—down 26.1% and 213bps YoY as percentage of sales. Maintain ‘HOLD’.
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. 
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
